FDC laroprovstat/Rosuvastatin not checked

AstraZeneca

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“daily oral dose of the Placebo to match laroprovstat or FDC laroprovstat/rosuvastatin”In the company’s words, NCT07930507 on ClinicalTrials.gov
Tested for
Hypercholesterolemia
Main trialPhase 3
“The purpose of this study is to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients with hypercholesterolaemia. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment of hypercholesterolaemia.”In the company’s words, NCT07930507 on ClinicalTrials.gov

Other drugs for Hypercholesterolemia

All 21 drugs for Hypercholesterolemia

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 11 Oct 2027 A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow FDC laroprovstat/Rosuvastatin

Following is part of Solo: you see every change to FDC laroprovstat/Rosuvastatin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in